29.06.20 ijBio Portfolio

Pharm Involved.

$1,000,000 on 12.06.20 Changes for 29.06.20:

AstraZeneca (AZN) $51,3 $52,9 (+3.1%) $103,100

Inovio (INO) $13,2 $31,7 (+140,1%) $240,100

Moderna (MRNA)$61,5 $62 (+0.8%) $100,800

Abbot (ABT) $88,5 $89 (+0.6%) $100,600

Gilead (GILD) $72,5 $74,6 (+2.9%) $102,900

Adaptive (ADPT) $42,2 $46 (+9%) $109,000

CytoDyn (CYDY) $3,12 $8,77 (+181%) $281,100

AbbVie (ABBV) $92,2 $96,4 (+4.5%) $104,500

Arcus (RCUS) $27,3 $23,6 (-13,5%) $86,500

Sorrento (SRNE) $4,6 $6,11 (+32,8%) $132,800

At close 29.06.20=$1,361,400 (+6,4%)

per million dollars at 10% per share.

previous day

At close 26.06.20= $1,279,600

during the two weeks 12-26.06.2020:+28% and

during the week 19-26.06.2020:+21%

At close 19.06.20= $1,057,700

during the week 12-19.06 +6%

12.06.20 = $1,000,000

Global Communication Platforms portfoilio

--

Portfolio News:

PRESS DIGEST- New York Times business news - June 30

Canada federal court dismisses drugmakers' plea challenging drug price rules

Sanofi (SNY) Gains But Lags Market: What You Should Know

Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know

Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know

Johnson & Johnson (JNJ) Gains But Lags Market: What You Should Know

US Indexes Close With Gains Monday

Gilead Discloses Pricing Plans for Covid-19 Treatment Remdesivir. What It Means for the Stock.

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for First-Line Treatment of Patients With Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer

US STOCKS-Wall St ends higher on Boeing bump, stimulus eyed

Coronavirus update: Global COVID-19 case tally tops 10 million and Florida, South Carolina and Nevada set daily records

3 “Strong Buy” Coronavirus Stocks With Massive Upside Potential

Abbott Laboratories (ABT): Were Hedge Funds Right About This Stock

GRAPHIC-Pandemic leads to six months of global market mayhem

US STOCKS-Wall St gains on Boeing bump, remdesivir hope

Gilead’s coronavirus drug will cost $2,340 — which sounds expensive, but here’s why it’s not

ER physician on Remdesivir COVID-19 treatment: 'I worry this will be a very expensive endeavor'

Race for a COVID-19 vaccine has drug makers scaling up manufacturing — before one is developed

Can Gilead Sciences Retest $85 High on Remdesivir Pricing Update?

Infojet Club

With help but without the assistance of Yahoo Finance

Advertise With Us